Bilcare
BSE: BI · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bilcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bilcare Ltd. is a provider of pharmaceutical packaging solutions, global clinical services, and research and development services. The company also specialises in anti-counterfeit technology branded as nCid.
Business Model
The company generates revenue through the provision of specialised packaging materials and clinical research services to the pharmaceutical industry. Following recent NCLT proceedings, the company's operating assets were acquired by its subsidiary, Caprihans India Ltd., to facilitate debt repayment.
Management Commentary
Management has focused on resolving long-standing debt defaults through a one-time settlement process concluded in 2023. The restructuring involved leveraging the balance sheet of its subsidiary to satisfy lender obligations.
Growth Outlook
The company's outlook is tied to the operational stability achieved post-settlement and the integration of its assets under the subsidiary structure. Future growth depends on the revitalisation of its core pharmaceutical packaging and research service offerings.
Key Risks
- Operational Continuity. The company faces significant challenges in restoring full operational capacity following years of financial distress and NCLT proceedings.
- Financial Leverage. The reliance on subsidiary balance sheets for asset acquisition and debt settlement creates complex inter-company dependencies.
- Market Competition. The pharmaceutical packaging and clinical research sectors are highly competitive, requiring constant innovation to maintain market share.
- Regulatory Compliance. As a provider to the healthcare sector, the company must adhere to stringent global quality and safety standards, which are costly to maintain.
Start your research today
Unlock AI insights, financials, peers and live data on Bilcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹734 Cr
TTM · consolidated
NET PROFIT
₹54 Cr
TTM · consolidated
EPS
₹15.05
TTM · consolidated
RETURN ON EQUITY
13.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-110.0%
TTM · consolidated
P/E
4.2x
Q4 FY26 · consolidated
EV/EBITDA
4.4x
Q4 FY26 · consolidated
EBITDA MARGIN
23.1%
TTM · consolidated
NET PROFIT MARGIN
4.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
3.1x
Q4 FY26 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
BilcareBI | ₹216 Cr | 6.10 | 4.92 | -6.9% | 23.1% | 13.4% | -110.0% | +32.4% |
Indegene Ltd.INDGN | ₹13,950 Cr | 34.65 | 19.04 | 30.4% | 18.8% | 13.9% | 17.4% | +6.8% |
Suven Life Sciences LimitedSUVEN | ₹9,624 Cr | -24.51 | -27.84 | 17.3% | -557.4% | -100.5% | -99.8% | +70.6% |
Vimta LabsVIMTALABS | ₹2,759 Cr | 34.59 | 17.54 | 15.2% | 37.3% | 19.1% | 24.1% | -7.3% |
Fabtech Technologies LimitedFABTECH | ₹656 Cr | 10.68 | 8.96 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹239 Cr | 18.77 | 38.28 | — | 7.4% | 49.8% | 24.2% | +60.9% |
As of Q4 FY26
Financials
Bilcare
BSE: BI · Healthcare Research, Analytics & Technology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bilcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bilcare Ltd. is a provider of pharmaceutical packaging solutions, global clinical services, and research and development services. The company also specialises in anti-counterfeit technology branded as nCid.
Business Model
The company generates revenue through the provision of specialised packaging materials and clinical research services to the pharmaceutical industry. Following recent NCLT proceedings, the company's operating assets were acquired by its subsidiary, Caprihans India Ltd., to facilitate debt repayment.
Management Commentary
Management has focused on resolving long-standing debt defaults through a one-time settlement process concluded in 2023. The restructuring involved leveraging the balance sheet of its subsidiary to satisfy lender obligations.
Growth Outlook
The company's outlook is tied to the operational stability achieved post-settlement and the integration of its assets under the subsidiary structure. Future growth depends on the revitalisation of its core pharmaceutical packaging and research service offerings.
Key Risks
- Operational Continuity. The company faces significant challenges in restoring full operational capacity following years of financial distress and NCLT proceedings.
- Financial Leverage. The reliance on subsidiary balance sheets for asset acquisition and debt settlement creates complex inter-company dependencies.
- Market Competition. The pharmaceutical packaging and clinical research sectors are highly competitive, requiring constant innovation to maintain market share.
- Regulatory Compliance. As a provider to the healthcare sector, the company must adhere to stringent global quality and safety standards, which are costly to maintain.
Start your research today
Unlock AI insights, financials, peers and live data on Bilcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹734 Cr
TTM · consolidated
NET PROFIT
₹54 Cr
TTM · consolidated
EPS
₹15.05
TTM · consolidated
RETURN ON EQUITY
13.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-110.0%
TTM · consolidated
P/E
4.2x
Q4 FY26 · consolidated
EV/EBITDA
4.4x
Q4 FY26 · consolidated
EBITDA MARGIN
23.1%
TTM · consolidated
NET PROFIT MARGIN
4.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
3.1x
Q4 FY26 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q4 FY26